Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, genetic analysis specialist Illumina
With that in mind, let's take a closer look at Illumina's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||San Diego, Calif. (1998)|
|Market Cap||$8.85 billion|
|Industry||Life sciences tools and services|
|Trailing-12-Month Revenue||$902.74 million|
|Management||CEO Jay Flatley (since 1999)
CFO Christian Henry (since 2005)
|Return on Equity (Average, Past 3 Years)||9.1%|
|Cash / Debt||$894.3 million / $311.6 million|
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
Earlier this month, fundamentalsrock tapped Illumina as a great way to go for growth: "DNA sequencing is moving into mainstream pharma, and Illumina has the market share and technology. They will dominate for the foreseeable future a fast, fast growing market."
Over the next five years, Illumina is even expected to grow its bottom line at a brisk rate of 27.5% annually. That's faster than listed rivals like Affymetrix (7.5%), Beckman Coulter (8.9%), and General Electric (12.8%).
CAPS member RedDave expands on the outperform case:
Both research and medicine are rapidly becoming dependent on deep sequencing. We are now moving into a time where DNA sequencing is truly as important as a microscope. Illumina has a daunting lead. Even giants can become complacent, and this market has numerous "Davids" looking to pick up some scraps.
Until a very long sequence read technology is developed that can reliably produce single reads of over 10,000 bases, it is Illumina's market to lose. The wide-moat is filling.
What do you think about Illumina, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.